《盈利預喜》興科蓉醫藥(06833.HK)料去年虧轉盈賺2,200萬至3,200萬人幣
興科蓉醫藥(06833.HK)發盈喜,預期至去年12月底止年度,錄純利2,200萬至3,200萬元人民幣,而2018年為虧損2.81億元人民幣。公司指,錄虧轉盈主因內地醫藥行業於2017及2018年執行「兩票制」,集團已完成了對銷售渠道及營銷網絡的重建及重新開發,因此,與2019年上半年度的情況一致,集團於本期間的銷售及經銷開支較同期整體減少;集團已償還很大部份於同期存在的計息銀行借款,故本期間的財務成本較同期減少。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.